GSK 2981278
Alternative Names: GSK-2981278Latest Information Update: 28 Jul 2023
At a glance
- Originator GlaxoSmithKline
- Class Antipsoriatics; Pyrans; Small molecules; Sulfonamides
- Mechanism of Action Nuclear receptor subfamily 1 group F member 3 inverse agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Plaque psoriasis
Most Recent Events
- 31 Jan 2020 Discontinued - Phase-II for Plaque psoriasis in Germany (Topical) before January 2020 (GlaxoSmithKline pipeline, January 2020)
- 05 May 2017 GlaxoSmithKline completes a phase II trial in Plaque psoriasis in Germany (Topical) (NCT03004846)
- 13 Feb 2017 Phase-II clinical trials in Plaque psoriasis in Germany (Topical) (NCT03004846)